Bortezomib resistance in multiple myeloma is associated with increased serine synthesis

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis

Abstract Background The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in cancer development and aid in the cellular adaptatio...

Full description

Bibliographic Details
Main Authors: Esther A. Zaal, Wei Wu, Gerrit Jansen, Sonja Zweegman, Jacqueline Cloos, Celia R. Berkers
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Cancer & Metabolism
Subjects:
Metabolism
Drug resistance
Bortezomib
Multiple myeloma
PHGDH
Online Access:http://link.springer.com/article/10.1186/s40170-017-0169-9

Internet

http://link.springer.com/article/10.1186/s40170-017-0169-9

Similar Items